The chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]
Published: August 29th 2025 | Updated: September 2nd 2025
Published: July 28th 2025 | Updated: July 30th 2025
Published: May 14th 2025 | Updated: May 16th 2025
Published: May 12th 2025 | Updated: May 13th 2025
Published: March 27th 2025 | Updated: March 28th 2025
Published: March 4th 2025 | Updated: March 19th 2025
